Oppenheimer Welcomes Joel Berry II and Expands North Carolina Private Client Team Focused on Advising Athletes

NEWS PROVIDED BY

Oppenheimer & Co. Inc.

Aug 31, 2026, 06:00 ET

SHARE THIS ARTICLE

Addition Strengthens Robinson Private Client Group's Work with Athletes and Participants in the Evolving NIL Landscape

NEW YORK, Aug. 31, 2026 /PRNewswire/ -- Oppenheimer & Co. Inc. ("Oppenheimer"), a leading wealth manager and investment bank and a subsidiary of Oppenheimer Holdings Inc. (NYSE: OPY), today announced that Joel Berry II has joined the firm as a Financial Advisor with the Robinson Private Client Group in Winston-Salem, North Carolina.

Led by Tanner G. Robinson, AIF®, CFP®, Managing Director and Financial Advisor, the team advises high-net-worth individuals and families, elite athletes, institutions and corporations. Its highly customized approach combines disciplined investment management with proactive financial planning and a high-touch service model. As of June 30, 2026, the Robinson Private Client Group advised on more than $6 billion in client assets.

Berry joins Oppenheimer after several years with Truist Financial and will help expand the Robinson Private Client Group's work with current and former athletes, including student-athletes navigating the evolving Name, Image and Likeness (NIL) and revenue-sharing landscape.

"We are pleased to welcome Joel to Oppenheimer," said Ed Harrington, Executive Vice President and Head of Oppenheimer's Private Client Division. "He has a clear vision for how he wants to serve clients and build his practice, and our job is to help him bring that vision to life. That means giving him the platform and resources needed to succeed."

During his career, Berry has worked closely with athletes, including professional players and high school and collegiate student-athletes adjusting to the financial opportunities created by NIL. His own experience in college and professional basketball gives him a firsthand understanding of the pressures, responsibilities and decisions that can come with athletic success.

Before entering wealth management, Berry was a four-year starter and team captain for the University of North Carolina (UNC) men's basketball team. He earned his bachelor's degree from UNC and helped lead the Tar Heels to the 2017 NCAA national championship, earning Final Four Most Outstanding Player honors. He later played professional basketball and currently works as a commentator for the ACC Network.

"Joel brings real-world experience advising individuals, families and business owners, along with firsthand insight into the financial lives of athletes," Robinson said. "He understands how to build lasting relationships, ask the right questions and help clients make thoughtful decisions as their circumstances change. His perspective will strengthen our team and help us expand the range of people we serve."

Berry concluded, "My own career showed me how quickly life can change and how valuable it is to have trusted advice along the way. I bring that perspective to every client relationship, whether I am working with a family, a business owner or an athlete. Oppenheimer and the Robinson Private Client Group give me the resources and expertise to help people plan with confidence and make sound decisions about their future."

About Oppenheimer Holdings Inc.

Oppenheimer Holdings Inc., through its principal subsidiary Oppenheimer & Co. Inc. and related entities, provides a full range of wealth management, securities brokerage and investment banking services to high-net-worth individuals, families, corporate executives, businesses and institutions. For more information, please visit www.oppenheimer.com.

Media Contact:

Michael Dugan

Haven Tower Group LLC

424-317-4852

mdugan@haventower.com

SOURCE Oppenheimer & Co. Inc.

21%

more press release views with 

Request a Demo

Operation Homefront® Welcomes Dr. Mike Witt to National Board of Directors

NEWS PROVIDED BY

Operation Homefront

Aug 31, 2026, 06:00 ET

SHARE THIS ARTICLE

SAN ANTONIO, Aug. 31, 2026 /PRNewswire/ -- Operation Homefront®, a leading national military nonprofit dedicated to serving America's military and veteran families, today announced the election of Dr. Mike Witt to its national board of directors. Witt is a seasoned C-level executive with more than 28 years of leadership experience in publicly traded multinational companies operating in highly regulated industries, and currently serves as Chief Environment, Quality & Safety Officer for Northrop Grumman Corporation. His proven ability to lead complex organizations and drive sustainable growth will be an asset to Operation Homefront as it continues its critical mission to provide relief and recurring support for military families across the nation.

Witt is a seasoned C-level executive with more than 28 years of leadership experience in publicly traded multinational companies operating in highly regulated industries, and currently serves as Chief Environment, Quality & Safety Officer for Northrop Grumman Corporation.

"We are honored to add a leader of Mike's caliber to our board," said retired Rear Adm. Alan Reyes, President and CEO of Operation Homefront. "Mike's distinguished career navigating complex corporate environments while driving sustainable growth will help position our organization to expand our impact and better meet the evolving needs of military and veteran families."

"I am honored to join the Operation Homefront Board of Directors and support an organization that makes a meaningful difference in the lives of military families," said Witt. "Throughout my career, I have been fortunate to achieve many professional milestones, but few opportunities carry the personal significance of serving those who sacrifice so much for our country."

Operation Homefront provides critical financial assistance, transitional and permanent housing, and family support services to prevent short-term needs from turning into chronic, long-term struggles for military and veteran families.

As a member of the Operation Homefront Board of Directors, Witt will bring executive oversight to an organization managing more than $40 million annually in impactful programming to tens of thousands of military families facing financial hardships, particularly as they transition out of service back to their civilian communities.

"It is a privilege to welcome Mike to our board," said Karen Genneken, Chair of Operation Homefront's Board of Directors. "His accomplished career, combined with his dedication to giving back, will help guide and strengthen our efforts to build strength and resilience in the military and veteran families we serve."

About Dr. Witt:

Dr. Mike Witt is a seasoned executive with a proven track record of driving transformational results across global operations, innovation and safety. With more than 28 years of experience in building high-performing teams and leveraging advanced AI capabilities to improve quality and safety outcomes, he has successfully led complex global initiatives while collaborating with stakeholders across business, government, academia, investors, and the nonprofit sector.

Witt currently serves as Chief Environment, Quality & Safety Officer for Northrop Grumman, reporting directly to Chair, CEO, and President Kathy Warden. He established and unified the company's corporate EH&S, energy, and operational risk functions, helping reduce safety incidents, strengthen risk management, and align sustainability and safety goals with executive compensation. A trusted advisor to senior leadership and the Board, he combines operational expertise with strategic vision. Witt earned engineering degrees from the University of Michigan and Michigan State University, an MBA in strategy from Northwood University, and is a frequent speaker at leading global business and policy forums.

About Operation Homefront: Operation Homefront is a national nonprofit organization whose mission is to build strong, stable, and secure military and veteran families by improving their financial, emotional and social well-being. Recognized for superior performance by leading independent charity oversight groups, 85 percent of Operation Homefront expenditures go directly to programs that support tens of thousands of military families each year. Operation Homefront provides critical financial assistance, transitional and permanent housing, and family support services to prevent short-term needs from turning into chronic, long-term struggles. Thanks to the generosity of our donors and the support from thousands of volunteers, Operation Homefront proudly serves America's military families. For more information, visit OperationHomefront.org.

SOURCE Operation Homefront

21%

more press release views with 

Request a Demo

IDEAYA Biosciences Announces Successful FDA Type C Meeting for IDE849, DLL3 TOP1 ADC, on Phase 3 Registrational Trial Design for Potential Accelerated and Full Approval in Extensive Stage Small Cell Lung Cancer

NEWS PROVIDED BY

IDEAYA Biosciences, Inc.

Aug 31, 2026, 06:00 ET

SHARE THIS ARTICLE

Based on FDA Type C meeting, targeting to initiate a randomized Phase 3 registrational trial for IDE849 monotherapy by year-end 2026 in ES-SCLC, with ORR by BICR as the primary endpoint for potential accelerated approval and median OS as the primary endpoint for potential full approval

Dose evaluation ongoing of 2.4mg/kg and 3.5 mg/kg IV Q3W to determine the RP3D

Target enrollment for the Phase 3 study will be ~400 ES-SCLC patients, randomized 1:1 treatment vs. investigator's choice

Clinical data updates for IDE849 in 100 ES-SCLC and NEC patients by partner Hengrui at ESMO 2026 and the IDEAYA sponsored Phase 1/2 clinical trial in ES-SCLC and NEC in Q4 2026 to support a potential best-in-class profile

IDE849 is being evaluated in clinical combinations with PDL1 and IDEAYA's PARG inhibitor IDE161 to determine a potential 1L SCLC Phase 3 registrational trial design

SOUTH SAN FRANCISCO, Calif., Aug. 31, 2026 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced a successful FDA Type C meeting to determine the Phase 3 registrational trial design for IDE849, a potential best-in-class delta-like ligand 3 (DLL3)-targeting Topo-I-payload antibody drug conjugate (ADC), in extensive stage small cell lung cancer (ES-SCLC). IDEAYA is targeting to initiate the Phase 3 registrational study in ES-SCLC by year-end 2026.

"Based on the FDA Type C meeting, we are targeting to initiate a randomized Phase 3 registrational study for IDE849 monotherapy in extensive stage small cell lung cancer to enable a potential accelerated approval and full approval in one seamless study design," said Yujiro S. Hata, President and Chief Executive Officer, IDEAYA Biosciences. "We also look forward to the clinical data updates at ESMO 2026 and later this year from our company sponsored clinical trial in ES-SCLC and NEC to support a potential best-in-class profile."

The anticipated enrollment target for the IDEAYA-sponsored global Phase 3 registrational study is approximately 400 ES-SCLC patients with prior tarlatamab treatment. The study will be randomized 1:1 between the treatment and an investigator's choice control arm that will include topotecan and ambrucin. The primary endpoint for accelerated approval will be overall response rate (ORR) by blinded independent central review (BICR) and the primary endpoint for full approval will be median overall survival. The secondary endpoints will include median duration of response by BICR, progression free survival, safety, among others.

IDEAYA has an ongoing multi-site global Phase 1 clinical trial for IDE849 in DLL3 upregulated solid tumor indications, including SCLC, and neuroendocrine carcinomas (NEC) (NCT07174583). The study is enrolling patients globally, including in North America, Europe, Australia, South America, and Asia. In this ongoing Phase 1 dose escalation study, IDE849 is currently evaluating the expansion doses of 2.4 mg/kg and 3.5 mg/kg IV once every 3-weeks (Q3W) to determine the recommended Phase 3 dose (RP3D).

In addition, IDE849 is being evaluated in clinical combination study with AstraZeneca's PDL1 inhibitor Imfinzi, and IDEAYA's potential first-in-class Phase 1 PARG inhibitor, IDE161, to determine a potential first-line (1L) SCLC Phase 3 registrational trial design. IDE161 prevents the removal of poly(ADP-ribose) chains generated by PARP during the DNA damage response, leading to persistent PARylation and impaired resolution of DNA repair complexes. Together with TOP1-payload ADCs, this unique mechanism-of-action results in sustained TOP1 cleavage complexes and the accumulation of DNA damage that delivers enhanced anti-tumor activity. We believe this potential first-in-class combination has the potential to enhance durability of IDEAYA's TOP1-payload based ADC pipeline, including IDE849 and IDE034 (Phase 1 B7H3/PTK7 Bispecific TOP1 ADC).

DLL3 has been reported to be upregulated in multiple solid tumor types, including in SCLC, NEC and melanoma, among others. IDEAYA estimates the annual incidence of SCLC and NEC in the United States is approximately 34,000 and 19,000 patients, respectively. DLL3 has limited extracellular expression in normal tissues, making it a promising potential therapeutic target in these solid tumors, for which there remains significant unmet medical need.

About IDEAYA Biosciences

IDEAYA is a precision medicine oncology company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. IDEAYA's approach integrates capabilities in identifying and validating translational biomarkers with drug discovery to select patient populations most likely to benefit from its targeted therapies. IDEAYA is applying its research and drug discovery capabilities to synthetic lethality – which represents an emerging class of precision medicine targets.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other applicable securities laws. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, but not limited to, statements regarding IDEAYA's interpretation of, and the anticipated regulatory implications arising from, feedback received during the FDA Type C meeting for IDE849; the potential design, initiation, timing, enrollment, conduct and completion of a randomized Phase 3 registrational trial evaluating IDE849 monotherapy in patients with extensive-stage small cell lung cancer previously treated with tarlatamab (Imdelltra); the potential for such trial to support accelerated approval based on overall response rate by blinded independent central review and subsequent full approval based on median overall survival; the anticipated size, randomization, treatment arms, control therapies and endpoints of the Phase 3 trial; the evaluation of doses and the timing and selection of a recommended Phase 3 dose; the timing, availability, content and significance of clinical data updates from Hengrui and IDEAYA-sponsored clinical trials, including anticipated presentations at ESMO 2026 and clinical data updates in the fourth quarter of 2026; the potential safety, efficacy, tolerability, durability, clinical activity and therapeutic benefits of IDE849, including its potential best-in-class profile; the development and evaluation of IDE849 in combination with Imfinzi and IDE161; the potential design and initiation of a Phase 3 registrational trial in first-line small cell lung cancer; the potential first-in-class profile and mechanism of action of IDE161; the potential for IDE161 to enhance the activity or durability of IDEAYA's TOP1-payload ADC pipeline, including IDE849 and IDE034; the prevalence and therapeutic relevance of DLL3 expression across solid tumors; and the potential clinical and regulatory development of IDE849, IDE161 and IDE034.

Such forward-looking statements are based on IDEAYA's management's current expectations, assumptions and beliefs and involve risks, uncertainties, and other factors that could cause actual results, including those related to IDEAYA's clinical programs, regulatory activities, commercial activities and performance or achievements, to differ significantly or materially from those expressed or implied by the forward-looking statements.

Such risks and uncertainties include, among others, risks relating to the FDA's feedback from regulatory meetings is preliminary and nonbinding, and the FDA may subsequently require modifications to the proposed Phase 3 trial design, endpoints, patient population, statistical analysis plan or regulatory strategy, or may require additional clinical or nonclinical data or one or more additional trials; the FDA may determine that overall response rate does not support accelerated approval or that the trial results do not verify clinical benefit or support full approval; IDEAYA may experience delays in selecting a recommended Phase 3 dose or initiating, enrolling, conducting or completing clinical trials; clinical trial results, including interim, preliminary or topline results, may not be reproduced in later trials or may not support further development or regulatory approval; IDE849, IDE161 or IDE034 may not demonstrate the safety, efficacy, tolerability, durability, clinical activity or differentiated profile anticipated; combination therapies may result in unexpected toxicities or may not demonstrate additive or synergistic clinical benefit; data may be delayed, incomplete, inconsistent or unfavorable; regulatory authorities may not accept IDEAYA's proposed development or approval strategies; and IDEAYA may encounter difficulties arising from patient enrollment, clinical-site activation, drug supply, manufacturing, competition, reliance on third parties and other factors. For a further description of risks and uncertainties that could cause actual results to differ from those expressed in or implied by these forward-looking statements, as well as risks relating to IDEAYA's business generally, is included in IDEAYA's filings with the Securities and Exchange Commission, including its most recent Annual Report on Form 10-K, filed on February 17, 2026, subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K.

Forward-looking statements speak only as of the date of this press release, and IDEAYA undertakes no obligation to update or revise any forward-looking statements contained herein to reflect any change in expectations, new information, subsequent events or circumstances, or otherwise, except as required by law.

Investor and Media Contact

IDEAYA Biosciences

Joshua Bleharski, Ph.D.

Chief Financial Officer

investor@ideayabio.com

SOURCE IDEAYA Biosciences, Inc.

21%

more press release views with 

Request a Demo

Ziihera® (zanidatamab-hrii) plus Chemotherapy Demonstrates Statistically Significant Overall Survival Benefit Versus Trastuzumab plus Chemotherapy in First-Line HER2+ Advanced GEA

NEWS PROVIDED BY

Jazz Pharmaceuticals plc

Aug 31, 2026, 06:00 ET

SHARE THIS ARTICLE

HERIZON-GEA-01 results reinforce recently FDA-approved Ziihera as the definitive HER2-targeted backbone therapy in first-line GEA

Longer follow up of Ziihera plus tislelizumab and chemotherapy shows improved OS hazard ratio, further supporting this regimen as the new standard of care

Data submitted for presentation in fourth quarter 2026

For U.S. media and investors only 

DUBLIN, Aug. 31, 2026 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced second interim top-line overall survival (OS) results from the Phase 3 HERIZON-GEA-01 trial showing that Ziihera® (zanidatamab-hrii) in combination with chemotherapy demonstrated statistically significant and clinically meaningful improvements in OS compared with trastuzumab plus chemotherapy as first-line treatment for adults with HER2-positive (HER2+) locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The Ziihera plus chemotherapy OS hazard ratio improved compared with the first interim analysis.

"Advanced HER2+ GEA remains an aggressive cancer with a poor prognosis, and trastuzumab plus chemotherapy has anchored first-line treatment for years. These HERIZON-GEA-01 results show that Ziihera-based regimens extend OS, demonstrating definitive superiority of Ziihera over trastuzumab and setting a new benchmark for what a first-line HER2-targeted therapy can achieve," said Dr. Kohei Shitara, director of the Department of Gastrointestinal Oncology, and principal trial investigator at the National Cancer Center Hospital East, Kashiwa, Japan.

The safety profile of Ziihera in combination with chemotherapy was generally consistent with the known safety profile of each agent and the previously reported data from HERIZON-GEA-01, with no new safety signals observed.

With longer follow up, the Ziihera plus Tevimbra® (tislelizumab-jsgr) and chemotherapy OS hazard ratio improved compared with the first interim analysis. These results build on the previous positive data, published in The New England Journal of Medicine, further demonstrating statistically significant, clinically meaningful and durable OS improvement for Ziihera plus tislelizumab and chemotherapy.  

"These results reinforce our confidence that Ziihera is the new HER2-targeted backbone therapy in first-line HER2+ advanced GEA, replacing trastuzumab and extending survival beyond the current standard of care," said Rob Iannone, M.D., M.S.C.E., executive vice president, global head of research and development, and chief medical officer of Jazz Pharmaceuticals. "Following the recent FDA approval, and further supported by these updated results, we are moving quickly to establish Ziihera as the HER2-targeted, first-line therapy of choice, with Ziihera plus tislelizumab and chemotherapy as the new standard of care in the United States."

On August 25, 2026, the FDA approved Ziihera in combination with tislelizumab and chemotherapy, for the first-line treatment of adults with HER2+ (IHC 3+ and IHC 2+/ISH+) unresectable locally advanced or metastatic GEA, and Ziihera in combination with chemotherapy in the same setting for patients with HER2+ (IHC 3+) disease. 

Jazz has submitted these data for presentation at a major medical meeting in the fourth quarter 2026 and will also submit these data to global health authorities.

The U.S. Prescribing Information for Ziihera contains Boxed Warnings for diarrhea and embryo-fetal toxicity.

Additional Important Safety Information related to Ziihera use in GEA is provided below. Please see full Prescription, including Boxed Warnings at https://pp.jazzpharma.com/pi/ziihera.en.USPI.pdf.

About the Phase 3 HERIZON-GEA-01 Trial

HERIZON-GEA-01 (NCT05152147) is a global, randomized, open-label Phase 3 trial, conducted jointly with BeOne Medicines, to evaluate and compare the efficacy and safety of zanidatamab plus chemotherapy, with and without tislelizumab, to trastuzumab plus chemotherapy as first-line treatment for adult patients with advanced/metastatic HER2+ GEA. The trial randomized 914 patients from approximately 225 trial sites in more than 30 countries. Appropriate patients for this trial had unresectable locally advanced, recurrent or metastatic HER2+ GEA (adenocarcinomas of the stomach or esophagus, including the gastroesophageal junction), defined as 3+ HER2 expression by IHC or 2+ HER2 expression by IHC with ISH positivity per central assessment. Patients were randomized to the three trial arms: zanidatamab in combination with chemotherapy and tislelizumab; zanidatamab in combination with chemotherapy; and trastuzumab plus chemotherapy. The trial evaluated dual primary endpoints, PFS per blinded independent central review (BICR) and OS.

About Gastroesophageal Adenocarcinoma

GEA, including cancers of the stomach, gastroesophageal junction, and esophagus, is the fifth most common cancer worldwide, and approximately 20% of patients have HER2+ disease.1,2,3,4 HER2+ GEA has high morbidity and mortality, and patients are urgently in need of new treatment options. The overall prognosis for patients with GEA remains poor, with a global five-year survival rate of less than 10% for patients with metastatic disease.5,6

About Ziihera® (zanidatamab-hrii)

Ziihera (zanidatamab-hrii) is a bispecific HER2-directed antibody that binds to two extracellular sites on HER2. Binding of zanidatamab with HER2 results in internalization leading to a reduction in HER2 expression of the receptor on the tumor cell surface. Zanidatamab induces CDC, ADCC, and ADCP. These mechanisms result in tumor growth inhibition and cell death in vitro and in vivo.7 

Gastroesophageal adenocarcinoma (GEA): In the United States, Ziihera is indicated for the first-line treatment of adults with HER2+ locally advanced or metastatic gastroesophageal adenocarcinoma (GEA), including cancers of the stomach, gastroesophageal junction and esophagus, in combination with tislelizumab-jsgr and fluoropyrimidine- and platinum-containing chemotherapy (HER2+ IHC 3+ and IHC 2+/ISH+ as detected by an FDA-authorized test); and in combination with fluoropyrimidine- and platinum-containing chemotherapy (HER2+ IHC 3+ as detected by an FDA-authorized test).

Biliary tract cancer (BTC): In the United States, Ziihera is also indicated for the treatment of adults with previously treated, unresectable or metastatic HER2+ (IHC 3+) biliary tract cancer (BTC), as detected by an FDA-approved test.7 Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).7 Ziihera is also approved in the European Union and other countries.

Zanidatamab is being developed in multiple clinical trials as a targeted treatment option for patients with solid tumors that express HER2. Zanidatamab is being developed by Jazz and BeOne under license agreements from Zymeworks, which first developed the molecule.  

The FDA granted three Breakthrough Therapy designations for zanidatamab's development: one as a single agent for previously treated HER2 gene-amplified BTC; one in combination with fluoropyrimidine- and platinum-containing chemotherapy, with or without tislelizumab for first-line HER2+ unresectable locally advanced or metastatic gastric, gastroesophageal junction (GEJ), or esophageal GEA; and one for the treatment of adults with previously treated, locally advanced, unresectable, or metastatic HER2+ colorectal cancer (CRC). The FDA also granted two Fast Track designations for zanidatamab: one as a single agent for refractory BTC and one in combination with standard-of-care chemotherapy for first-line GEA. Additionally, zanidatamab has received Orphan Drug designations from the FDA for the treatment of BTC, gastric (including GEJ) cancer, and esophageal cancer, as well as Orphan Drug designations from the European Medicines Agency for the treatment of BTC, gastric/gastroesophageal junction cancer, and esophageal cancer. Jazz continues to pursue additional regulatory approvals for zanidatamab in markets worldwide.  

Important Safety Information for ZIIHERA   

WARNING: DIARRHEA and EMBRYO-FETAL TOXICITY

ZIIHERA, in combination with fluoropyrimidine- and platinum-containing chemotherapy, with or without tislelizumab-jsgr, can cause severe diarrhea, including life threatening and fatal cases. Use antidiarrheal prophylaxis during the first cycle when ZIIHERA is given in combination with these drugs. Manage with antidiarrheals and supportive measures as clinically indicated. Interrupt, reduce the dose or discontinue ZIIHERA based on severity. 

Embryo-Fetal Toxicity: Exposure to ZIIHERA during pregnancy can cause embryo-fetal harm. Advise patients of the risk and need for effective contraception.

Diarrhea: ZIIHERA can cause severe diarrhea.

When ZIIHERA is used in combination with fluoropyrimidine- and platinum-containing chemotherapy with or without tislelizumab-jsgr, severe, life threatening, and fatal cases of diarrhea can occur despite loperamide prophylaxis. The risk of severe and life threatening diarrhea is higher when ZIIHERA is administered with chemotherapy and tislelizumab-jsgr, with a higher risk in patients aged ≥ 65 years compared to younger patients. Advise patients to increase oral fluids, begin antidiarrheals, and notify their healthcare provider immediately if diarrhea occurs.

Administer antidiarrheal prophylaxis with loperamide in cycle 1 for all patients receiving ZIIHERA in combination with fluoropyrimidine- and platinum-containing chemotherapy with or without tislelizumab-jsgr. Begin loperamide at the first loose stool when ZIIHERA is administered in combination with chemotherapy. Administer fluids, electrolytes, and additional antidiarrheal agents as necessary. Before modifying the dose of ZIIHERA, evaluate, modify or discontinue drug(s) contributing to diarrhea in accordance with their respective prescribing information. Withhold, reduce the dose, or permanently discontinue ZIIHERA based on severity.

If treating patients with ZIIHERA in combination with FOLFOX, do not administer the fluorouracil bolus.

ZIIHERA in combination with chemotherapy and tislelizumab-jsgr

Diarrhea was reported in 85% of 330 patients in clinical studies, including Grade 4 (2.1%), Grade 3 (24%), and Grade 2 (31%) events. Fatal outcomes resulting from diarrhea occurred in 1.5% of patients. Diarrhea leading to dose reduction of ZIIHERA occurred in 10% of patients, and permanent discontinuation of ZIIHERA occurred in 3.9% of patients.

In cycle 1, diarrhea at Grade 4 severity occurred in 1.5% and Grade 3 severity occurred in 15% of patients despite use of loperamide prophylaxis. The median time to onset for cycle 1 diarrhea was 6 days and median time to resolution was 18 days.

ZIIHERA in combination with chemotherapy

Diarrhea was reported in 81% of 395 patients in clinical studies, including Grade 4 (1.3%), Grade 3 (20%) and Grade 2 (33%). Diarrhea leading to dose reduction of ZIIHERA occurred in 10% of patients, and permanent discontinuation of ZIIHERA occurred in 1.8% of patients.

In cycle 1, diarrhea at Grade 4 severity occurred in 0.8% and Grade 3 severity occurred in 14% of patients despite use of loperamide prophylaxis. The median time to onset for cycle 1 diarrhea was 6 days and median time to resolution was 18 days.

Embryo-Fetal Toxicity: Based on the mechanism of action, ZIIHERA can cause fetal harm when administered to a pregnant woman. There are no human or animal data on the use of ZIIHERA in pregnancy. In literature reports, use of a HER2-directed antibody during pregnancy resulted in cases of oligohydramnios and oligohydramnios sequence manifesting as pulmonary hypoplasia, skeletal abnormalities, and neonatal death.

Verify the pregnancy status of females of reproductive potential prior to the initiation of ZIIHERA. Advise pregnant women and females of reproductive potential that exposure to ZIIHERA during pregnancy or within 4 months prior to conception can result in fetal harm. Advise females of reproductive potential to use effective contraception while receiving ZIIHERA and for 4 months following the last dose of ZIIHERA.

Left Ventricular Dysfunction (LVD): ZIIHERA can cause decreases in left ventricular ejection fraction (LVEF).

Assess LVEF prior to initiation of ZIIHERA and at regular intervals during treatment. Withhold dose or permanently discontinue ZIIHERA based on severity of adverse reactions.

The safety of ZIIHERA has not been established in patients with a baseline ejection fraction that is 50%.

ZIIHERA in combination with chemotherapy and tislelizumab-jsgr

LVEF decrease (an absolute decline in LVEF of > 10%, resulting in a final value of 50%) was observed in 9% of 330 patients in clinical studies. LVD leading to permanent discontinuation of ZIIHERA was reported in 3% of patients. Fatal outcomes due to LVD occurred in one patient (0.3%). The median time to first occurrence of LVD was 6.9 months (range: 1.2 to 29.1 months). LVD resolved in 78% of patients.

ZIIHERA in combination with chemotherapy

LVEF decrease was observed in 5% of 395 patients. LVD leading to permanent discontinuation of ZIIHERA was reported in 1.0% of patients. The median time to first occurrence of LVD was 6.0 months (range: 1.4 to 15.0 months). LVD dysfunction resolved in 70% of patients.

Infusion-Related Reactions: ZIIHERA can cause infusion-related reactions (IRRs).

Prior to each dose of ZIIHERA, administer premedication to prevent potential IRRs. Monitor patients for signs and symptoms of IRR during ZIIHERA administration and as clinically indicated after completion of infusion. Have medications and emergency equipment to treat IRRs available for immediate use.

If an IRR occurs, slow or stop the infusion, and administer appropriate medical management. Monitor patients until complete resolution of signs and symptoms before resuming. Permanently discontinue ZIIHERA in patients with recurrent severe or life-threatening IRRs.

ZIIHERA in combination with chemotherapy and tislelizumab-jsgr

An IRR was reported in 22% of 330 patients in clinical studies, including Grade 4 (0.3%), Grade 3 (1.2%), and Grade 2 (16%) despite use of prophylaxis. IRRs leading to permanent discontinuation of ZIIHERA were reported in 0.3% of patients. IRRs occurred on the first day of dosing in 17% of patients. Of all patients who experienced IRRs, 60% of reactions resolved within the first day.

ZIIHERA in combination with chemotherapy

An IRR was reported in 24% of 395 patients in clinical studies, including Grade 4 (0.3%), Grade 3 (1.5%), and Grade 2 (18%) despite use of prophylaxis. IRRs leading to permanent discontinuation of ZIIHERA were reported in 1.3% of patients. IRRs occurred on the first day of dosing in 22% of patients. Of all patients who experienced IRRs, 83% of reactions resolved within the first day.

Adverse Reactions

ZIIHERA in combination with chemotherapy and tislelizumab-jsgr

Serious adverse reactions occurred in 59% of 294 patients in HERIZON-GEA-01. Serious adverse reactions in > 2% of patients included diarrhea (17%), IRR (5%), vomiting (4.8%), hypokalemia (4.4%), acute kidney injury (3.7%), pneumonia (3.7%), nausea (2.4%), decreased appetite (2.4%), and anemia (2.4%). Fatal adverse reactions occurred in 2.4% of patients and included acute kidney injury (N=2), cardiac failure, diarrhea, dehydration, hypovolemic shock and intestinal obstruction (all N=1).

Permanent discontinuation of ZIIHERA occurred in 13% of patients. Adverse reactions that resulted in permanent discontinuation of ZIIHERA in ≥ 1% of patients included diarrhea (4.4%) and ejection fraction decreased (2.7%).

The most common adverse reactions (≥ 20%) were diarrhea (83%), nausea (56%), decreased appetite (46%), vomiting (44%), hypokalemia (39%), fatigue (37%), rash (36%), peripheral neuropathy (27%), and IRR (25%).

ZIIHERA in combination with chemotherapy

Serious adverse reactions occurred in 49% of 305 patients in HERIZON-GEA-01. Serious adverse reactions in > 2% of patients included diarrhea (11%), vomiting (3.3%), decreased appetite (2.6%), pneumonia (2.6%), sepsis (2.6%), hypokalemia (2.3%), and nausea (2.3%).

Permanent discontinuation of ZIIHERA occurred in 10% of patients. Adverse reactions that resulted in permanent discontinuation of ZIIHERA in ≥ 1% of patients included ejection fraction decreased (2.0%), IRR (1.6%), and diarrhea (1.6%).

The most common adverse reactions (≥ 20%) were diarrhea (79%), nausea (54%), vomiting (44%), decreased appetite (40%), fatigue (36%), hypokalemia (33%), peripheral neuropathy (32%), IRR (25%), and rash (22%).

Pediatric Use: Safety and efficacy of ZIIHERA have not been established in pediatric patients.

Geriatric Use

ZIIHERA in combination with chemotherapy and tislelizumab-jsgr

Of 302 patients randomized to ZIIHERA in combination with chemotherapy and tislelizumab-jsgr in HERIZON-GEA-01, there were 139 (46%) patients aged ≥ 65 years. One hundred and six (35%) were aged 65-74 years and 33 (11%) were aged ≥ 75 years.

There was a higher incidence of Grade ≥ 3 adverse reactions observed in patients aged ≥ 65 years (87%) as compared to younger patients (80%). The incidence of Grade 3 or 4 diarrhea was higher in patients aged ≥ 65 years (32%) compared to younger patients (20%).

There was an increased incidence of fatal adverse reactions in patients aged ≥ 65 years (4.4%); including acute kidney injury (N=2), cardiac failure, dehydration, hypovolemic shock and intestinal obstruction (all N=1), compared to younger patients (0.6%), including diarrhea (N=1).

ZIIHERA in combination with chemotherapy

Of 304 patients randomized to ZIIHERA in combination with chemotherapy in HERIZON-GEA-01, there were 130 (43%) patients aged ≥ 65 years. One hundred (33%) were aged 65-74 years and 30 (10%) were aged ≥ 75 years.

No overall differences in safety were observed between patients aged ≥ 65 years and younger adult patients.

® TEVIMBRA (tislelizumab) is a registered trademark of BeOne Medicines.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) is a global biopharma company whose purpose is to innovate to transform the lives of patients and their families. We are dedicated to developing life-changing medicines for people with rare disease — often with limited or no therapeutic options. We have a diverse portfolio of medicines, including leading therapies addressing epilepsies, cancers and sleep disorders. Our patient-focused and science-driven approach powers pioneering research and development advancements across our robust pipeline of innovative therapeutics. Jazz is headquartered in Dublin, Ireland with research and development laboratories, manufacturing facilities and employees in multiple countries committed to serving patients worldwide. Please visit www.jazzpharmaceuticals.com for more information. 

Cautionary Note concerning Forward-Looking Statements

This press release contains forward-looking statements, including, but not limited to, statements related to Ziihera's potential to extend survival, Ziihera's potential as a new standard of care in HER2+ first-line GEA and other HER2-expressing cancers and other statements that are not historical facts. These forward-looking statements are based on Jazz Pharmaceuticals' current plans, objectives, estimates, expectations and intentions and inherently involve significant risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, risks and uncertainties associated with the successful completion of regulatory activities and uncertain regulatory approval, risks related to failure or delays in successfully initiating or completing clinical trials and assessing patients and other risks and uncertainties affecting Jazz Pharmaceuticals and its development programs, including those described from time to time under the caption "Risk Factors" and elsewhere in Jazz Pharmaceuticals' Securities and Exchange Commission filings and reports, including Jazz Pharmaceuticals' Annual Report on Form 10-K for the year ended December 31, 2025, and future filings and reports by Jazz Pharmaceuticals. Other risks and uncertainties of which Jazz Pharmaceuticals is not currently aware may also affect Jazz Pharmaceuticals' forward-looking statements and may cause actual results and the timing of events to differ materially from those anticipated. The forward-looking statements herein are made only as of the date hereof or as of the dates indicated in the forward-looking statements, even if they are subsequently made available by Jazz Pharmaceuticals on its website or otherwise. Jazz Pharmaceuticals undertakes no obligation to update or supplement any forward-looking statements to reflect actual results, new information, future events, changes in its expectations or other circumstances that exist after the date as of which the forward-looking statements were made. 

Contacts:

Media:

CorporateAffairsMediaInfo@jazzpharma.com

Ireland +353 1 637 2141

U.S. +1 215 867 4948

Investors:

InvestorInfo@jazzpharma.com

Ireland +353 1 634 7800

U.S. +1 650 496 2717

_______________________________

1

Bray F., et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians. 2024 April; doi.org/10.3322/caac.21834Digital Object Identifier (DOI)

2

Abrahao-Machado I.F., et al. HER2 testing in gastric cancer: An update WorldJGastroenterol. 2016;22(19):4619-4625.

3

Van Custem E., et al. HER2 screening data from ToGA: targeting HER2 in gastric and gastroesophageal junction cancer. Gastric Cancer. 2015;18(3):476-484.

4

Stroes, C.I., et al. A systematic review of HER2 blockade for the curative treatment of gastroesophageal adenocarcinoma: Successes achieved and opportunities ahead. CancerTreatRev. 2021;99:102249.

5

National Cancer Institute. SEER Cancer Stat Facts: Stomach Cancer. Bethesda, MD. https://seer.cancer.gov/statfacts/html/stomach.html.

6

National Cancer Institute. SEER Cancer Stat Facts: Esophageal Cancer. Bethesda, MD. https://seer.cancer.gov/statfacts/html/esoph.html.

7

ZIIHERA (zanidatamab-hrii) Prescribing Information. Palo Alto, CA: Jazz Pharmaceuticals, Inc.

SOURCE Jazz Pharmaceuticals plc

21%

more press release views with 

Request a Demo

Realtor.com® Ranks the Top Metros for New Construction in 2026

NEWS PROVIDED BY

Realtor.com

Aug 31, 2026, 06:00 ET

SHARE THIS ARTICLE

 Charleston takes No. 1 as new-home listing prices are 12.2% below existing homes; Southern markets claim eight of the top 10 spots 

AUSTIN, Texas, Aug. 31, 2026 /PRNewswire/ -- Eight of the 10 best metros for purchasing a newly built home are in the South, according to the second annual Realtor.com® Top Metros for New Construction report, led by Charleston-North Charleston, S.C., where the median newly built home is priced 12.2% below the median existing home. The ranking finds that markets with builder-friendly conditions are giving buyers more opportunity to find a new home with a competitive price, ample availability and strong demand.

Charleston takes the top spot among the 100 largest U.S. metros, earning an overall score of 84.7 out of 100. The metro's median new-build listing price is $443,273, compared with $504,832 for existing homes, the strongest new-construction price advantage among the top 10 markets. Greenville-Anderson-Greer, S.C., ranks second, followed by Boise City, Idaho.

"New construction is one of the most important ways to expand the supply of homes available to buyers, but the opportunity is not evenly distributed across the country," said Joel Berner, senior economist at Realtor.com®. "This year's ranking shows that Southern metros are not only building more homes; they are also creating conditions where buyers can find newly built homes at prices that compete with, and in some cases beat, existing homes."

The Top 10 Metros for New Construction in 2026

Metro

New

Construction

Share of

Listings

New

Construction

Premium

Climate Risk

Score vs

Existing

Homes

Page Views

per New

Construction

Listing vs

National

Average

New

Construction

Days on Market

Charleston-North Charleston, SC

24.8 %

-12.2 %

-0.5 %

-6.9 %

48

Greenville-Anderson-Greer, SC

33.4 %

-1.6 %

3.1 %

8.3 %

60

Boise City, ID

53.4 %

-4.5 %

6.1 %

-21.6 %

61

Charlotte-Concord-Gastonia, NC-SC

29.5 %

4.7 %

0.3 %

1.5 %

65

Nashville-Davidson--Murfreesboro--Franklin, TN

30.1 %

5.1 %

2.7 %

-19.1 %

52

Chattanooga, TN-GA

26.8 %

10.1 %

-2.4 %

20.1 %

66

Winston-Salem, NC

33.0 %

9.7 %

3.2 %

15.9 %

64

Madison, WI

30.8 %

12.5 %

0.8 %

108.4 %

70

Durham-Chapel Hill, NC

33.0 %

8.7 %

-0.3 %

-18.8 %

68

Columbia, SC

25.5 %

-3.0 %

7.2 %

-0.4 %

45

Carolinas Dominate as Smaller, Growing Metros Lead

Six of the top 10 metros are in North or South Carolina, and two more are in Tennessee. Together, these eight Southern markets underscore how local building conditions can shape the availability and relative affordability of new homes. More permissive zoning, less restrictive building codes and lower land costs can make it easier for builders to deliver new housing in the South.

The list is also dominated by small-to-midsize metros. Charlotte, the nation's 20th-largest metro, is the largest market in the top 10; Nashville, ranked 35th by size, is next. No other metro in the top 10 ranks among the 50 largest U.S. metropolitan areas.

"Markets such as Charleston, Greenville and Boise are demonstrating what new-home buyers value most: choice and pricing that make a newly built home a realistic option," Berner said. "The concentration of top performers in smaller, high-growth metros is a reminder that housing supply responds to local conditions. When communities make it feasible to build, buyers have more options."

College towns also remain prominent in the ranking, with nearly every top-10 metro anchored by a major research university or flagship school. These institutions support local employment, talent pipelines and economic growth, helping sustain demand for new homes.

What Sets the Top Markets Apart

The 2026 ranking evaluates the 100 largest U.S. metros by household count across four weighted measures:

New-construction share of listings (33%)

New-construction premium, or the percentage difference between median new-build and existing-home listing prices (33%)

Difference in average flood, fire, air-quality, wind and heat risk between new and existing homes (17%)

New-construction market hotness, based on page views per listing and median time on market (17%)

Madison is the only Midwestern metro in the ranking and has the strongest new-construction shopper interest among the top 10, with page views per listing running 108.4% above the national average. The ranking includes one Western metro, Boise, and no Northeast metros.

Honorable Mentions

Metro

New

Construction

Share of

Listings

New

Construction

Premium

Climate Risk

Score vs

Existing

Homes

Page Views

per New

Construction

Listing vs

National

Average

New

Construction

Days on Market

Richmond, VA

35.7 %

20.7 %

-1.5 %

5.4 %

65

Raleigh-Cary, NC

41.9 %

1.8 %

5.1 %

-19.1 %

69

Cape Coral-Fort Myers, FL

20.1 %

-12.9 %

-0.6 %

-2.4 %

75

San Antonio-New Braunfels, TX

34.0 %

2.9 %

8.2 %

-57.2 %

59

Spokane-Spokane Valley, WA

18.5 %

4.3 %

1.7 %

-4.5 %

53

Austin-Round Rock-San Marcos, TX

32.8 %

-8.1 %

6.7 %

-48.1 %

71

Augusta-Richmond County, GA-SC

32.6 %

3.9 %

4.5 %

-40.0 %

82

McAllen-Edinburg-Mission, TX

24.0 %

3.4 %

4.9 %

-24.8 %

67

Greensboro-High Point, NC

28.6 %

19.7 %

3.9 %

12.8 %

70

Houston-Pasadena-The Woodlands, TX

28.6 %

9.3 %

6.6 %

-68.4 %

59

Wichita, KS

29.6 %

8.1 %

8.5 %

47.6 %

89

Dallas-Fort Worth-Arlington, TX

31.0 %

9.8 %

13.6 %

-9.5 %

68

Lakeland-Winter Haven, FL

26.8 %

-1.4 %

6.7 %

-29.0 %

77

Knoxville, TN

18.9 %

16.7 %

1.5 %

87.9 %

69

Portland-South Portland, ME

14.4 %

15.2 %

-2.1 %

359.5 %

64

Methodology

Listing data were collected from Realtor.com® listings between January 1 and June 30, 2026. Scores are percentile ranks for each metric among the 100 largest metros by household count. New-construction share measures listings designated as new construction as a share of total metro listings. The new-construction premium compares the average monthly median listing prices of new and existing homes. Climate-risk data from First Street cover flood, fire, air quality, wind and heat risk. Market hotness combines page views per listing on Realtor.com® and time on market for new-construction listings.

Read the full 2026 Top New-Construction Metros report.

About Realtor.com®

For over 30 years, Realtor.com® has connected buyers, sellers, and renters with trusted insights, professional guidance and powerful tools to help them find their perfect home. Recognized as the No. 1 real estate site REALTOR® agents recommend, Realtor.com® delivers consumer connections and a robust suite of marketing tools to support business growth. Realtor.com® is operated by News Corp [Nasdaq: NWS, NWSA] [ASX: NWS, NWSLV] subsidiary Move, Inc.

Media Contact: Mallory Micetich, press@realtor.com 

SOURCE Realtor.com

21%

more press release views with 

Request a Demo

So-Young Reports Unaudited Second Quarter 2026 Financial Results

NEWS PROVIDED BY

So-Young International Inc.

Aug 31, 2026, 06:00 ET

SHARE THIS ARTICLE

BEIJING, Aug. 31, 2026 /PRNewswire/ -- So-Young International Inc. (Nasdaq: SY) ("So-Young" or the "Company"), the leading aesthetic treatment platform in China connecting consumers with online services and offline treatments, today announced its unaudited financial results for the second quarter ended June 30, 2026.

Second Quarter 2026 Financial Highlights

Total revenues were RMB505.2 million (US$74.5 million[1]), an increase of 33.4% from RMB378.7 million in the corresponding period of 2025. The aesthetic treatment services revenues were RMB331.4 million (US$48.8 million), an increase of 129.5% from RMB144.4 million in the corresponding period of 2025, exceeding the high end of guidance.

Net loss attributable to So-Young International Inc. was RMB22.7 million (US$3.3 million), compared with net loss attributable to So-Young International Inc. of RMB36.0 million in the same period of 2025.

Non-GAAP net loss attributable to So-Young International Inc.[2] was RMB21.0 million (US$3.1 million), compared with non-GAAP net loss attributable to So-Young International Inc. of RMB30.5 million in the same period of 2025.

Second Quarter 2026 Operational Highlights

The number of verified treatment visits to the branded aesthetic centers for the quarter reached approximately 165,200, an increase of 145% from approximately 67,400 in the same period of 2025. The number of verified aesthetic treatments performed surpassed 362,300, an increase of 134% from approximately 154,500 in the same period of 2025.

The number of active users, defined as those who visited branded aesthetic centers at least once during the 12-month period ended on June 30, 2026, exceeded 255,300, an increase of 154% from 100,400 users during the corresponding period in 2025.

The number of core members[3] grew by over 15,000 during the quarter, representing a sequential increase of approximately 24%. These core members contributed over 80% of aesthetic treatment services revenues, with a quarterly repurchase rate of nearly 70%.

As of June 30, 2026, So-Young had 65 fully operational branded aesthetic centers (63 directly-operated, 2 franchised) across eighteen major cities: Beijing, Shanghai, Guangzhou, Shenzhen, Hangzhou, Chengdu, Wuhan, Chongqing, Ningbo, Changsha, Tianjin, Xi'an, Suzhou, Hefei, Kunming, Nanjing, Jinan, and Foshan. Among them, 47 centers achieved profitability* in the second quarter of 2026. In addition, 51 centers generated positive quarterly operating cash flow* in the second quarter of 2026. Same-store sales growth** in this quarter was 52%, compared to 14% in the same quarter of 2025.

[1] This press release contains translations of certain Renminbi (RMB) amounts into U.S. dollars (US$) solely for the convenience of the reader. Unless otherwise specified, all translations of Renminbi amounts into U.S. dollar amounts in this press release are made at RMB6.7851 to US$1.00, which was the U.S. dollars middle rate announced by the Board of Governors of the Federal Reserve System of the United States on June 30, 2026.

[2] Non-GAAP net loss attributable to So-Young International Inc. is defined as net loss attributable to So-Young International Inc. excluding share-based compensation expenses. See "Reconciliation of GAAP and Non-GAAP Results" at the end of this press release.

[3] We categorize our user base across nine tiers (L0 through L8). Core members represent users at Tier L3 and above.

* Center-level profitability measures whether an individual aesthetic center achieved positive profit in a given period. It is calculated by deducting consumable materials costs, personnel costs, center rental expenses, center depreciation expenses, and other center-level operating costs from the company's self-operated store revenues, before allocation of any back-office or mid-office expenses. Quarterly operating cash flow refers to total cash collected from orders less center-level operating payments in a given period, and excluding operating expense payments made by back-office or mid-office departments during the same period. Center-level profitability and quarterly operating cash flow are metrics derived from the Company's internal management accounts, which have not been audited.

** Same-store sales growth represents the year-over-year growth in quarterly revenue from stores that are comparable and continuously operated during both the current quarter and the same quarter of the prior year.

Management Commentary

Mr. Xing Jin, Co-Founder and Chief Executive Officer of So-Young, commented, "Our sustained focus on scale and efficiency yielded another strong quarter for our core aesthetic treatment business. Supported by enhanced medical capabilities, a robust standardized delivery system, and deeper AI integration, we scaled our business more efficiently. This solid execution is validated by a 129.5% year-over-year increase in second-quarter aesthetic treatment services revenues with a 3.8 percentage-point expansion in segment gross margin. Going forward, we will further strengthen our supply chain and accelerate AI-powered transformation to deliver more competitive products and services across our expanding network, laying a solid foundation for sustainable, high-quality growth."

Ms. Shannon Shen, Chief Financial Officer of So-Young, added, "In the second quarter of 2026, our aesthetic treatment business exceeded RMB330 million in revenue, representing approximately 130% year-over-year growth and marking the tenth consecutive quarter of triple-digit expansion. This strong performance propelled our second-quarter total revenues to an all-time high of RMB505.2 million, up 33.4% year-over-year. While maintaining this rapid topline growth, we have remained highly focused on expansion quality and sustainability, striving for healthier unit economics and narrowing net loss attributable to the Company by 37.0% year-over-year. These results reaffirmed both our market insights and execution excellence, as we continued to enhance our medical service delivery, organizational capabilities, and supply chain management, while improving operational efficiency. Looking ahead, we see a clear path toward profitability as our industry leadership solidifies and economies of scale continue to unfold."

Second Quarter 2026 Financial Results

Revenues

Total revenues were RMB505.2 million (US$74.5 million), an increase of 33.4% from RMB378.7 million in the same period of 2025. The increase was primarily due to business expansion of the branded aesthetic centers.

Aesthetic treatment services revenues were RMB331.4 million (US$48.8 million), an increase of 129.5% from RMB144.4 million in the same period of 2025. The increase was primarily due to the business expansion of the branded aesthetic centers.

Information and reservation services revenues were RMB87.9 million (US$13.0 million), a decrease of 35.0% from RMB135.2 million in the same period of 2025. The decrease was primarily due to a decrease in the number of medical service providers subscribing to information services on So-Young's platform.

Sales of medical products and maintenance services revenues were RMB73.9 million (US$10.9 million), a decrease of 2.8% from RMB76.0 million in the same period of 2025, primarily due to a decrease in the order volume of medical equipment.

Other services revenues were RMB12.0 million (US$1.8 million), a decrease of 48.2% from RMB23.2 million in the same period of 2025, primarily due to a decrease in revenues from insurance brokerage services.

Cost of Revenues

Cost of revenues was RMB282.4 million (US$41.6 million), an increase of 53.0% from RMB184.6 million in the second quarter of 2025. The increase was primarily due to the business expansion of the branded aesthetic centers.

Cost of aesthetic treatment services was RMB238.4 million (US$35.1 million), an increase of 118.0% from RMB109.4 million in the second quarter of 2025. The increase was primarily due to the business expansion of the branded aesthetic centers.

Cost of information and reservation services was RMB5.2 million (US$0.8 million), a decrease of 68.7% from RMB16.7 million in the second quarter of 2025. The decrease was in line with the decrease in revenue generated from information and reservation services.

Cost of medical products sold and maintenance services was RMB29.9 million (US$4.4 million), a decrease of 24.3% from RMB39.5 million in the second quarter of 2025. The decrease was primarily due to a decrease in costs associated with the sales of medical equipment.

Cost of other services was RMB8.9 million (US$1.3 million), a decrease of 53.2% from RMB19.0 million in the second quarter of 2025. The decrease was primarily due to a decrease in costs associated with insurance brokerage services.

Operating Expenses

Total operating expenses were RMB266.5 million (US$39.3 million), an increase of 10.4% from RMB241.3 million in the second quarter of 2025.

Sales and marketing expenses were RMB153.5 million (US$22.6 million), an increase of 16.8% from RMB131.3 million in the second quarter of 2025. The increase was mainly due to higher branding and user acquisition activities expenses and increased payroll costs at the branded aesthetic centers.

General and administrative expenses were RMB88.6 million (US$13.1 million), an increase of 12.5% from RMB78.8 million in the second quarter of 2025. The increase was primarily due to the business expansion of the branded aesthetic centers.

Research and development expenses were RMB24.4 million (US$3.6 million), a decrease of 21.7% from RMB31.2 million in the second quarter of 2025. The decrease was primarily attributable to improvements in staff efficiency.

Income Tax Benefits/(Expenses)

Income tax benefits were RMB2.5 million (US$0.4 million), compared with income tax expenses of RMB1.9 million in the same period of 2025.

Net Loss Attributable to So-Young International Inc.

Net loss attributable to So-Young International Inc. was RMB22.7 million (US$3.3 million), compared with a net loss attributable to So-Young International Inc. of RMB36.0 million in the second quarter of 2025.

Non-GAAP Net Loss Attributable to So-Young International Inc.

Non-GAAP net loss attributable to So-Young International Inc., which excludes the impact of share-based compensation expenses, was RMB21.0 million (US$3.1 million), compared with RMB30.5 million non-GAAP net loss attributable to So-Young International Inc. in the same period of 2025.

Basic and Diluted Loss per ADS

Basic and diluted loss per ADS attributable to ordinary shareholders were RMB0.22 (US$0.03) and RMB0.22 (US$0.03), respectively, compared with basic and diluted loss per ADS attributable to ordinary shareholders of RMB0.35 and RMB0.35, respectively, in the same period of 2025.

Cash and Cash Equivalents, Restricted Cash and Term Deposits, Term Deposits and Short-Term Investments

As of June 30, 2026, cash and cash equivalents, restricted cash and term deposits, term deposits and short-term investments were RMB848.2 million (US$125.0 million), compared with RMB936.4 million as of December 31, 2025.

Business Outlook

For the third quarter of 2026, So-Young expects aesthetic treatment services revenues to be between RMB352.0 million (US$51.9 million) and RMB362.0 million (US$53.4 million), representing a 91.7% to 97.2% increase from the same period in 2025. The above outlook is based on the current market conditions and reflects the Company's preliminary estimates of market and operating conditions, as well as customer demand, which are all subject to change.

Non-GAAP Financial Measures

To supplement the financial measures prepared in accordance with generally accepted accounting principles in the United States, or GAAP, this press release presents non-GAAP loss from operations and non-GAAP net loss attributable to So-Young International Inc. by excluding share-based compensation expenses from loss from operations and net loss attributable to So-Young International Inc., respectively.

The Company believes these non-GAAP financial measures are important to help investors understand the Company's operating and financial performance, compare business trends among different reporting periods on a consistent basis and assess the Company's core operating results, as they exclude certain expenses (i) that are not expected to result in cash payments or (ii) that are non-recurring in nature or may not be indicative of the Company's core operating results and business outlook. The use of the above non-GAAP financial measures has certain limitations. Share-based compensation expenses are non-cash in nature. All these are not reflected in the presentation of the non-GAAP financial measures, but should be considered in the overall evaluation of the Company's results. The Company compensates for these limitations by providing the relevant disclosure of its share-based compensation expenses in the reconciliations to the most directly comparable GAAP financial measures, which should be considered when evaluating the Company's performance. These non-GAAP financial measures should be considered in addition to financial measures prepared in accordance with GAAP, but should not be considered a substitute for, or superior to, financial measures prepared in accordance with GAAP. Reconciliation of each of these non-GAAP financial measures to the most directly comparable GAAP financial measure is set forth at the end of this release.

Conference Call Information

So-Young's management will hold an earnings conference call on Monday, August 31, 2026, at 7:30 AM U.S. Eastern Time (7:30 PM on the same day, Beijing/Hong Kong Time). Dial-in details for the earnings conference call are as follows:

International:

+1-412-902-4272

China:

4001-201203

US:

+1-888-346-8982

Hong Kong:

+852-800-905945

Passcode:

So Young

A telephone replay will be available two hours after the conclusion of the conference call through 23:59 U.S. Eastern Time, September 7, 2026. The dial-in details are:

International:

+1-412-317-0088

US:

+1-855-669-9658

Passcode:

1697226

Additionally, a live and archived webcast of this conference call will be available at http://ir.soyoung.com.

About So-Young International Inc.

So-Young International Inc. (Nasdaq: SY) ("So-Young" or the "Company") is the leading aesthetic treatment platform in China connecting consumers with online services and offline treatments. The Company provides access to aesthetic treatments through its online platform and branded aesthetic centers, offering curated treatment information, facilitating online reservations, delivering high-quality treatments, and developing, producing and distributing optoelectronic medical equipment and injectable products. With its strong brand recognition, digital reach, affordable treatments and efficient supply chain, So-Young is well-positioned to serve its audience over the long term and grow along the medical aesthetic value chain.

Safe Harbor Statement

This announcement contains forward-looking statements. These statements are made under the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates," "confident" and similar statements. Among other things, the Financial Guidance and quotations from management in this announcement, as well as So-Young's strategic and operational plans, contain forward-looking statements. So-Young may also make written or oral forward-looking statements in its periodic reports to the U.S. Securities and Exchange Commission, in its annual report to shareholders, in press releases and other written materials and in oral statements made by its officers, directors or employees to third parties. Statements that are not historical facts, including but not limited to statements about So-Young's beliefs and expectations, are forward-looking statements. Forward looking statements involve inherent risks and uncertainties. A number of factors could cause actual results to differ materially from those contained in any forward-looking statement, including but not limited to the following: So-Young's strategies; So-Young's future business development, financial condition and results of operations; So-Young's ability to retain and increase the number of users and medical service providers, and expand its service offerings; competition in the online medical aesthetic service industry; changes in So-Young's revenues, costs or expenditures; Chinese governmental policies and regulations relating to the online medical aesthetic service industry, general economic and business conditions globally and in China; and assumptions underlying or related to any of the foregoing. Further information regarding these and other risks is included in the Company's filings with the Securities and Exchange Commission. All information provided in this press release and in the attachments is as of the date of the press release, and So-Young undertakes no duty to update such information, except as required under applicable law.

For more information, please contact:

So-Young

Investor Relations

Ms. Mona Qiao

Phone: +86-10-8790-2012

E-mail: ir@soyoung.com

Christensen

Ms. Joanna Quan

Phone: +86-10-5900-1548

E-mail: sy@christensencomms.com 

SO-YOUNG INTERNATIONAL INC.

UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS

(Amounts in thousands, except for share and per share data)

As of

December 31,

June 30,

June 30,

2025

2026

2026

RMB

RMB

US$

Assets

Current assets:

Cash and cash equivalents

418,213

442,584

65,229

Restricted cash and term deposits

64,683

63,450

9,351

Trade receivables

51,532

40,344

5,946

Inventories

233,389

253,584

37,374

Receivables from online payment platforms

16,296

25,049

3,692

Amounts due from related parties

774

756

111

Term deposits and short-term investments

453,472

342,137

50,425

Prepayment and other current assets

246,237

296,241

43,661

Total current assets

1,484,596

1,464,145

215,789

Non-current assets:

Long-term investments

274,753

277,236

40,860

Intangible assets

144,097

133,596

19,690

Goodwill

684

684

101

Property and equipment, net

293,560

336,054

49,528

Deferred tax assets

69,313

70,602

10,405

Operating lease right-of-use assets

251,635

257,343

37,928

Other non-current assets

130,998

138,995

20,485

Total non-current assets

1,165,040

1,214,510

178,997

Total assets

2,649,636

2,678,655

394,786

Liabilities

Current liabilities:

Short-term borrowings

39,814

113,141

16,675

Taxes payable

43,461

34,504

5,085

Contract liabilities

65,948

62,287

9,180

Salary and welfare payables

130,170

132,791

19,571

Amounts due to related parties

618

510

75

Accrued expenses and other current

liabilities

427,507

482,310

71,084

Operating lease liabilities-current

76,536

81,593

12,025

Total current liabilities

784,054

907,136

133,695

Non-current liabilities:

Operating lease liabilities-non current

183,364

183,551

27,052

Deferred tax liabilities

10,615

7,632

1,125

Other non-current liabilities

2,783

3,987

588

Total non-current liabilities

196,762

195,170

28,765

Total liabilities

980,816

1,102,306

162,460

Shareholders' equity:

Treasury stock

(391,944)

(391,944)

(57,765)

Class A ordinary shares (US$0.0005 par value; 750,000,000

   shares authorized as of December 31, 2025 and June 30,

   2026; 79,016,808 and 65,089,482 shares issued and

   outstanding as of December 31, 2025, 79,322,924 and

   65,395,598 shares issued and outstanding as of June 30,

   2026, respectively)

257

258

38

Class B ordinary shares (US$0.0005 par value; 20,000,000

   shares authorized as of December 31, 2025 and June 30,

   2026; 12,000,000 shares issued and outstanding as of

   December 31, 2025 and June 30, 2026)

37

37

5

Additional paid-in capital

3,059,764

3,064,102

451,593

Statutory reserves

46,448

46,448

6,846

Accumulated deficit

(1,174,587)

(1,246,455)

(183,705)

Accumulated other comprehensive income

13,340

(11,524)

(1,698)

Total So-Young International Inc. shareholders' equity

1,553,315

1,460,922

215,314

Non-controlling interests

115,505

115,427

17,012

Total shareholders' equity

1,668,820

1,576,349

232,326

Total liabilities and shareholders' equity

2,649,636

2,678,655

394,786

SO-YOUNG INTERNATIONAL INC.

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(Amounts in thousands, except for share and per share data)

For the Three Months Ended

For the Six Months Ended

June 30,

2025

June 30,

2026

June 30,

2026

June 30,

2025

June 30,

2026

June 30,

2026

RMB

RMB

US$

RMB

RMB

US$

Revenues:

Aesthetic treatment services

144,390

331,435

48,847

243,217

613,867

90,473

Information and reservation services

135,172

87,916

12,957

256,797

168,227

24,794

Sales of medical products and maintenance services

76,036

73,877

10,888

131,626

131,018

19,310

Other services

23,150

12,000

1,769

44,378

24,891

3,668

Total revenues

378,748

505,228

74,461

676,018

938,003

138,245

Cost of revenues:

Cost of aesthetic treatment services

(109,370)

(238,384)

(35,133)

(189,634)

(444,142)

(65,458)

Cost of information and reservation services

(16,705)

(5,224)

(770)

(40,002)

(11,625)

(1,713)

Cost of medical products sold and maintenance services

(39,491)

(29,880)

(4,404)

(69,916)

(60,283)

(8,885)

Cost of other services

(18,992)

(8,886)

(1,310)

(36,421)

(17,322)

(2,553)

Total cost of revenues

(184,558)

(282,374)

(41,617)

(335,973)

(533,372)

(78,609)

Gross profit

194,190

222,854

32,844

340,045

404,631

59,636

Operating expenses:

Sales and marketing expenses

(131,333)

(153,460)

(22,617)

(229,209)

(284,286)

(41,899)

General and administrative expenses

(78,786)

(88,617)

(13,061)

(138,070)

(173,121)

(25,515)

Research and development expenses

(31,177)

(24,403)

(3,597)

(63,286)

(48,742)

(7,184)

Total operating expenses

(241,296)

(266,480)

(39,275)

(430,565)

(506,149)

(74,598)

Loss from operations

(47,106)

(43,626)

(6,431)

(90,520)

(101,518)

(14,962)

Other income/(expenses):

Investment income, net

884

4,483

661

99

4,689

691

Interest income, net

7,948

2,550

376

14,973

6,284

926

Exchange gains

701

6,345

935

726

11,255

1,659

Share of losses of equity method investee

(1,012)

(178)

(26)

(3,454)

(365)

(54)

Others, net

5,663

3,274

483

10,497

1,545

228

Loss before tax

(32,922)

(27,152)

(4,002)

(67,679)

(78,110)

(11,512)

Income tax (expenses)/benefits

(1,877)

2,453

362

(272)

3,206

473

Net loss

(34,799)

(24,699)

(3,640)

(67,951)

(74,904)

(11,039)

Net (income)/loss attributable to noncontrolling interests

(1,240)

2,007

296

(1,226)

3,036

447

Net loss attributable to So-Young International Inc.

(36,039)

(22,692)

(3,344)

(69,177)

(71,868)

(10,592)

SO-YOUNG INTERNATIONAL INC.

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Continued)

(Amounts in thousands, except for share and per share data)

For the Three Months Ended

For the Six Months Ended

June 30,

2025

June 30,

2026

June 30,

2026

June 30,

2025

June 30,

2026

June 30,

2026

RMB

RMB

US$

RMB

RMB

US$

Net loss per ordinary share

Net loss per ordinary share attributable to ordinary shareholder - basic

(0.46)

(0.29)

(0.04)

(0.88)

(0.92)

(0.14)

Net loss per ordinary share attributable to ordinary shareholder - diluted

(0.46)

(0.29)

(0.04)

(0.88)

(0.92)

(0.14)

Net loss per ADS attributable to ordinary shareholders - basic (13 ADS represents

   10 Class A ordinary shares)

(0.35)

(0.22)

(0.03)

(0.68)

(0.71)

(0.10)

Net loss per ADS attributable to ordinary shareholders - diluted (13 ADS

   represents 10 Class A ordinary shares)

(0.35)

(0.22)

(0.03)

(0.68)

(0.71)

(0.10)

Weighted average number of ordinary shares used in computing loss per share,

   basic*

77,826,404

77,781,549

77,781,549

78,194,634

77,726,350

77,726,350

Weighted average number of ordinary shares used in computing loss per share,

   diluted*

77,826,404

77,781,549

77,781,549

78,194,634

77,726,350

77,726,350

Share-based compensation expenses included in:

Cost of revenues

(124)

—

—

(154)

(3)

—

Sales and marketing expenses

(598)

(228)

(34)

(728)

(315)

(46)

General and administrative expenses

(4,286)

(1,336)

(197)

(5,690)

(3,816)

(562)

Research and development expenses

(487)

(149)

(22)

(580)

(184)

(27)

* Both Class A and Class B ordinary shares are included in the calculation of the weighted average number of ordinary shares outstanding, basic and diluted.

SO-YOUNG INTERNATIONAL INC.

Reconciliation of GAAP and Non-GAAP Results

(Amounts in thousands, except for share and per share data)

For the Three Months Ended

For the Six Months Ended

June 30,

2025

June 30,

2026

June 30,

2026

June 30,

2025

June 30,

2026

June 30,

2026

RMB

RMB

US$

RMB

RMB

US$

GAAP loss from operations

(47,106)

(43,626)

(6,431)

(90,520)

(101,518)

(14,962)

Add back: Share-based compensation expenses

5,495

1,713

253

7,152

4,318

635

Non-GAAP loss from operations

(41,611)

(41,913)

(6,178)

(83,368)

(97,200)

(14,327)

GAAP net loss attributable to So-Young International Inc.

(36,039)

(22,692)

(3,344)

(69,177)

(71,868)

(10,592)

Add back: Share-based compensation expenses

5,495

1,713

253

7,152

4,318

635

Non-GAAP net loss attributable to So-Young International Inc.

(30,544)

(20,979)

(3,091)

(62,025)

(67,550)

(9,957)

SOURCE So-Young International Inc.

21%

more press release views with 

Request a Demo

Nevada Organic Phosphate Announces Continued Excellent Low Heavy Metal Assays for Drill Hole MM26-10 at Murdock Mountain and Promotional Activity Engagement

NEWS PROVIDED BY

Nevada Organic Phosphate Inc.

Aug 31, 2026, 05:35 ET

SHARE THIS ARTICLE

VANCOUVER, BC, Aug. 31, 2026 /PRNewswire/ -- Nevada Organic Phosphate Inc. ("NOP" or the "Company") (CSE: NOP) (OTCQB: NOPFF), a B.C. based leader in organic sedimentary phosphate exploration, is pleased to announce that the heavy metal contaminant assays from the Upper Phosphatic Zone in drill hole MM26-10 at Murdock Mountain, continue to demonstrate results well below the maximum allowed limits for Organic Fertilizer Certification. MM26‑10, a 1.5‑kilometre step‑out along strike at the Murdock Mountain project, returned another excellent intersection of 10.89% P2O5 over 3.60 metres. (See previous News Release dated August 26, 2026)

In the chart below, please note the SUIP #25 and the California values. NOP's Upper Phosphate Zone values are significantly lower than the maximum heavy metal values allowed.

California Heavy Metal Thresholds

41

39

1500

17

75

420

300

100

2800

SUIP #25 for 10% P2O5

130

100

1360

10

420

2500

610

260

4200

DDH

Sample

From m

To m

P2O5%

As

Cd

Co

Cu

Hg

Mo

Ni

Pb

Se

Zn

MM26-10

1121787

194.00

195.00

8.45

9.9

3.25

2.6

24.3

0.185

4.32

66.6

4.4

2

238

MM26-10

1121789

195.00

196.00

9.21

10.6

3.04

3.1

29.5

0.220

4.75

74.4

5.2

4

245

MM26-10

1121790

196.00

197.00

16.20

9.0

2.61

2.5

25.9

0.202

5.60

62.5

5.3

5

221

MM26-10

1121791

197.00

197.60

8.93

5.1

1.19

1.7

12.9

0.123

4.43

28.3

2.5

4

107

Note: the assays displayed above are the actual assays for each sample interval. Values are in ppm unless otherwise noted.

DDH

UTME

UTMN

Elev m

TD m

Dip

Az

MM26-10

722868

4567500

2181

215.04

-90

0

coordinates are NAD83 UTM

Robin Dow, CEO, stated: "This is another solid intersection from MM26‑10 demonstrating that the Upper Phosphatic Zone continues to deliver predictable, clean, very low heavy metals content criteria suitable for Organic Certification. We continue to meet our objectives, positioning NOP as a genuinely differentiated entrant in the fertilizer market."

In the United States, organic certification is governed by the USDA National Organic Program (USDA-NOP). The USDA-NOP does not publish its own numeric heavy-metal limits for mineral fertilizers like rock phosphate. Instead, certifiers rely on two things:

USDA-NOP 205.203(c) soil and plant amendments must not contaminate soil or crops with heavy metals. 

State fertilizer laws can vary, but almost universally adopt AAPFCO's SUIP #25 Heavy Metal Rule for determining whether a fertilizer is adulterated (AAPFCO, Association of American Plant Food Control Officials, created SUIP #25 to give states a consistent, science-based method for regulating heavy metals in fertilizers. It is not a law, but most states adopt it into their fertilizer programs).

USDA Organic Certification: For organic production, a rock phosphate fertilizer must:

Be mined, not chemically processed

Not contain synthetic additives

Not exceed heavy-metal levels that would contaminate soil or crops

Typically meet SUIP #25 limits (this is what certifiers check)

If a product meets these limits, it is generally acceptable for organic certification.

SUIP #25 sets limits per 1% P₂O₅. For fertilizer with 10% P₂O₅, multiply limit by 10.

Metal

Limit per 1% P2O5

Limit per 10% P2O5

Arsenic (As)

13

130

Cadmium (Cd)

10

100

Cobalt (Co)

136

1,360

Lead (Pb)

61

610

Mercury (Hg)

1

10

Molybdenum (Mo)

42

420

Nickel (Ni)

250

2,500

Selenium (Se)

26

260

Zinc (Zn)

420

4,200

Note: all values in ppm

These are the maximum allowable concentrations before a phosphate fertilizer is considered adulterated under U.S. state fertilizer laws.

Lab Assaying Methods & QA/QC

All sample preparation and analytical work was carried out by ALS Laboratories ("ALS"), an independent commercial laboratory accredited to ISO/IEC 17025:2017 for mineral analysis. Samples were delivered to the ALS Geochemistry in Elko, Nevada preparation facility and then forwarded to ALS Geochemistry in Vancouver for analysis. ALS operates under rigorous quality management systems and is regularly audited by recognized accreditation bodies, including the Standards Council of Canada (SCC) and the Canadian Association for Laboratory Accreditation (CALA).

Heavy metal assaying was by ME-MS61 trace element analysis: Samples were digested using a near-total four-acid procedure (HF; HNO₃; HClO₄; HCl) and analyzed by ICP-MS and ICP-AES. This technique delivers ultra-trace detection of a broad suite of elements, including deleterious or contaminant metals such as arsenic, cadmium, mercury, and lead, supporting environmental and processing assessments.

ALS maintains strict internal QA/QC protocols, including the insertion of certified reference materials, blanks, and duplicates with each batch of samples. These measures ensure that analytical results meet internationally recognized standards of accuracy and reliability, consistent with the requirements of NI 43-101 reporting.

Company Quality Assurance / Quality Control (QA/QC)

The Company implemented a rigorous QA/QC protocol consistent with NI 43-101 standards, including the insertion of blanks and certified reference materials into the sample stream.

Blanks: The Company regularly inserted a blank comprised of generically sourced sand every 11 samples (or 9.3%) to monitor potential contamination during sample preparation and analysis.

Certified reference materials ("CRM"): CRMs used in mineral exploration are used to assess analytical accuracy and are usually rock powders comprised of known concentrations of the metal(s) of interest. CRMs are usually obtained from commercial suppliers who provide the average of many analyses of the CRMs by multiple labs, which is referred to as the certified value, and a standard deviation of the analyses from which the certified value is determined. A typical criterion for accepting the analyses of CRMs in the mineral industry is that they should fall within a range determined by the certified (or "target") value ± three standard deviations ("3 STD"). Analytical accuracy was verified against BAM 826-1, a certified reference material for phosphate slags issued by Germany's Federal Institute for Materials Research and Testing (BAM). The Company inserted BAM 826-1 CRM standards every 22 samples (or 4.5%), or about 2 per drill hole.

The Company is satisfied that the QA/QC results demonstrate the reliability of the assay data and support the integrity of the phosphate grades reported herein.

Qualified Persons

All assays and detailed core logging interpretation has been provided by the Independent Qualified Person for this drill program, Kenneth N. Tullar, AIPG Certified Professional Geologist (CPG 11142). Mr. Tullar has reviewed and approved the technical data in this news release.

The interpretation of the technical information in this news release has been reviewed and approved by Garry K. Smith, P.Geo., a director of NOP and a Qualified Person as defined under National Instrument 43 101 – Standards of Disclosure for Mineral Projects.

Promotional Activity Engagement

The Company also announces it has entered into an independent consulting agreement (the "Agreement") dated August 25th, 2026, with Emerging Growth Research LLC. (the "Consultant"), pursuant to which the Consultant will act as an independent research provider. The consultant will prepare a report with the purpose to present an objective summary and analysis of the Company's operations, business model, industry, financial performance, and investment potential based on publicly available information (the "Report"). The Consultant will retain full editorial independence and control over the content of such Report. The Report will be distributed by the Consultant through FactSet, Bloomberg, LSEG Eikon, S&P Capital IQ, and made available on its website, its social media channels, and to conference attendees.

The Company has agreed to compensate the Consultant a fixed fee of USD $25,000 for research, production, and distribution services related to the Report. The initiation research report is expected to be drafted within four to six (4–6) weeks from the date of the Agreement.

Emerging Growth Research LLC. is an arm's length party to the Company and, to the knowledge of the Company, holds no securities of, and has no other interest, direct or indirect, in, the Company. All materials produced and disseminated under the Agreement will disclose that they are issued by or on behalf of, and paid for by, the Company, in accordance with applicable securities legislation.

The Consultant's contact information is as follows: 30 N. Gould Street Ste R, Sheridan, WY, 82801 USA, phone: 305-330-1985, and email: research@emerginggrowth.com.

Nevada Organic Phosphate Inc. (CSE: NOP) (OTCQB: NOPFF)

NOP is a junior exploration company with an organic sedimentary raw rock phosphate bed, 6.6 kilometres long, in northeast Nevada. Additional applications extend the potential strike of rock phosphate to over 30 kilometres. This is believed to be the only known large-scale organic sedimentary phosphate project in North America. It is situated close to the main highway to Montello/Elko, Nevada, and near the rail head to California or the East Coast.

Neither the Canadian Securities Exchange nor its regulations services providers have reviewed or accept responsibility for the adequacy or accuracy of this release.

This news release may contain forward-looking statements and information ("FLSI") within the meaning of applicable securities laws. FLSI may include expectations, anticipations, beliefs, opinions, plans, intentions, estimates, forecasts, projections, guidance or other similar statements and information that are not historical facts. All statements which are not historical statements are considered FLSI. All FLSI is based on assumptions, which may prove inaccurate, and subject to certain risks and uncertainties, including without limitation those risks and uncertainties identified in the Company's public securities filings, which may cause actual events or results to differ materially from those indicated or implied in FLSI. Accordingly, readers should not place undue reliance or value on FLSI. Although the Company believes that the expectations reflected in any FLSI in this news release are reasonable at the present time, it can give no assurance that such FLSI will prove to be correct. Any FLSI in this news release is made as of the date hereof and the Company undertakes no obligations to publicly update or revise any FLSI, whether as a result of new information, future events or otherwise, unless required by applicable securities laws. Any FLSI in this news release is expressly qualified in its entirety by this cautionary statement.

SOURCE Nevada Organic Phosphate Inc.

21%

more press release views with 

Request a Demo

Data Dynamics Launches Enterprise 2.0.5 at LEAP 2026, Bringing Governed AI to the Data Layer

NEWS PROVIDED BY

Data Dynamics Software Solutions

Aug 31, 2026, 05:59 ET

SHARE THIS ARTICLE

With 60% of AI projects stalled due to data curation and AI readiness, Enterprise 2.0.5 puts governance where it's actually enforceable, at the data itself.

RIYADH, Saudi Arabia, Aug. 31, 2026 /PRNewswire/ -- Data Dynamics, a global leader in data management, announced Enterprise 2.0.5's general availability at LEAP 2026. The release closes a gap entities hit while scaling AI: models pointed at unmapped data, agents granted standing access to content, and compliance teams proving control 'after the fact'.

Data Dynamics Launches Enterprise 2.0.5 at LEAP 2026

As of 2026, 114 countries have enacted national data protection and privacy laws, touching 3 in every 4 citizens globally. An example of this is Saudi Arabia's PDPL, enforced by the Saudi Data and Artificial Intelligence Authority (SDAIA), carries 48 enforcement decisions. SDAIA also sets the Kingdom's AI strategy, so data and AI governance sit under one regulator, and the cost of inaction is rising on both fronts.

Enterprise 2.0.5 answers both problems at the data layer. Its 'Bring Your Own Model' (BYOM) architecture lets organizations run any model inside their own trust boundary. Content-aware, time-bound entitlements bring models, agents and people under one framework, with grants that expire by design. An on-demand compliance audit produces attestable evidence in minutes; lifecycle tools retire redundant data before it reaches a GPU cluster, creating a compute-efficiency win.

"AI programs don't stall because the models aren't good enough. They stall because no one can say what the data is, who should be allowed to touch it, or whether using it is compliant," said Piyush Mehta, CEO of Data Dynamics. "Understand your data and prove it's governed, and AI stops being a risk conversation and becomes a speed advantage. That is what Enterprise 2.0.5 provides!"

Enterprise 2.0.5 is generally available across cloud, on-premises, sovereign and air-gapped deployments.

About Data Dynamics

Data Dynamics helps the world's largest enterprises make their data safe to use with AI. The company is built on a single premise: data that cannot be found, classified, or governed cannot be secured and trusted by AI. Its Software discovers and classifies data natively across languages, brings people, models and agents under a single content-aware access framework, curates AI-ready datasets with sensitive content protected, and quantifies data risk across every deployment. Ownership, accountability and residency never leave the organization that holds the data. Sovereignty by design.

Photo: https://mma.prnewswire.com/media/3008916/Data_Dynamics_Enterprise_launch.jpg

Logo: https://mma.prnewswire.com/media/3008915/Data_Dynamics_Logo.jpg

SOURCE Data Dynamics Software Solutions

21%

more press release views with 

Request a Demo

Sowell Management Expands Advisor Support Platform with Launch of Advanced Planning Group

NEWS PROVIDED BY

Sowell Management

Aug 31, 2026, 06:00 ET

SHARE THIS ARTICLE

Value-added offering adds integrated estate, tax, and advanced planning capabilities to help advisors better serve affluent families and navigate their increasingly complex needs

NORTH LITTLE ROCK, Ark., Aug. 31, 2026 /PRNewswire/ -- Sowell Management (Sowell), a leading Registered Investment Advisor (RIA) serving financial advisors and their clients nationwide, announced the launch of its Advanced Planning Group (APG), a new integrated estate, tax and advanced planning resource designed to support its advisors and the high-net-worth families, wealthy individuals and small business owners they serve. APG will be available for advisors across both the Sowell Management and Cache River Private Wealth platforms.

JR Quraishi, Director of Tax Planning; Carrie Quraishi, Director of Advanced Planning; Bill Sowell, founder and Chief Strategy Officer, Sowell Management

Led by Carrie Quraishi, JD, Director of Advanced Planning, and JR Quraishi, Director of Tax Planning, APG provides advisors access to specialized expertise in estate planning, tax strategy, business succession planning, asset protection, wealth transfer planning and family legacy planning.

"As clients accumulate wealth, their financial lives become increasingly complex, with needs that extend beyond traditional investment management," said Bill Sowell, founder and Chief Strategy Officer, Sowell Management. "The launch of our Advanced Planning Group reinforces Sowell's ongoing focus on partnership, organic growth and delivering truly differentiating resources that help advisors navigate complexity with confidence."

APG reflects Sowell's continued commitment to investing in resources that help advisors deepen relationships, strengthen their value proposition and better serve affluent clients through increasingly sophisticated planning opportunities.

Carrie Quraishi said, "High-Net-Worth clients are increasingly expecting a similar level of elite service that was once the exclusive domain of family offices. The addition of APG allows Sowell to offer the services these clients deserve, while expanding our ability to support them through significant life and wealth events, including business sales, liquidity events, succession planning, and multi-generational wealth transfer."

An important feature of APG is to identify proactive tax planning opportunities and integrate sophisticated tax strategies into all its services to ensure clients mitigate their tax burden as much as possible. APG's tax overlay discipline of is led by JR Quraishi.

The launch of APG is part of a broader effort to expand planning resources available to advisors and affluent families across the Sowell ecosystem and will play an important role within Cache River Private Wealth, helping families address sophisticated planning needs involving wealth transfer, family stewardship, business succession, tax planning, and long-term legacy objectives.

Cache River Private Wealth was launched in April of 2026 as a wholly owned division of Sowell Management purpose-built to serve the growing high-net-worth market of households with $5 million+ in net worth. The new division is home to discerning advisors and families, where planning, investing and expertise converge to create a distinctive wealth management experience.

About Sowell Management

Sowell Management is a privately held Registered Investment Advisor (RIA) and a trusted partner to financial advisors. Founded by financial advisor Bill Sowell in 2001, Sowell Management provides a transformative platform of services and solutions to guide advisors on the path toward true independence. Sowell has a nationwide network of financial advisors representing over $6.9 billion* in client assets (AUA/AUM) as of June 2026.

*Regulatory assets under management (AUM) are assets where Sowell provides continuous and regular supervisory or management services to client portfolios. Assets under administration (AUA) is a measure of the total assets for which Sowell provides administrative services. Working with a highly rated advisor does not ensure that a client or prospective client will experience a higher level of performance or results. 

For more information, visit sowellmanagement.com.

Media Contact

Haven Tower Group

Brandon Blackwell

(424) 317-4868

bblackwell@haventower.com

SOURCE Sowell Management

21%

more press release views with 

Request a Demo

Best Design Software for Small Businesses (2026): CorelDRAW Features and Workflows Highlighted by Consumer365

NEWS PROVIDED BY

Consumer365.org

Aug 31, 2026, 05:30 ET

SHARE THIS ARTICLE

NEW YORK, Aug. 31, 2026 /PRNewswire/ -- Consumer365 has published a new review of CorelDRAW Graphics Suite 2026, analyzing how the professional design toolkit serves small businesses with print-intensive work. The assessment gives priority to the operational needs of print shops, followed by sign shops, apparel and screen-printing businesses, in-house marketing teams, and professional designers.

Best Design Software for Small Businesses

CorelDRAW - professional graphic design software for creating layouts, graphics, typography, edited images, and print-ready artwork

Rather than treating design software as a creative application alone, the assessment looks at the full path from client-supplied artwork to finished output. Color separations, soft proofing, work at 1:1 scale, prepress controls, file compatibility, and purchasing choice form the basis of the evaluation.

What Makes Print Production an Important Test?

Small print businesses often handle artwork, page setup, image correction, type, proofing, and final output within the same team. Each handoff between applications can add extra file conversions, review steps, or production checks.

CorelDRAW Graphics Suite brings several tasks into one toolkit:

CorelDRAW provides vector illustration and page layout.

Corel PHOTO-PAINT handles pixel-based image editing.

Corel Font Manager organizes type libraries without requiring every font to be installed.

CorelDRAW Web gives subscribers browser-based graphic design tools

This structure can help a shop take a job from initial artwork through prepress without relying on a separate application for every stage.

How Does CorelDRAW Support Print-Ready Output?

CorelDRAW includes tools for color separations, soft proofing, print preview, and color management. Pantone Color Libraries are included at no additional charge, giving teams a shared reference for setting color expectations before production.

For signage and other large-format work, artwork can be prepared at 1:1 scale. Multipage view allows several pages or assets to be managed together, while multi-asset export creates a defined export list for pages and objects. Support for numerous graphics, publishing, and image formats also helps when customers or vendors submit files from different systems.

The 2026 edition adds AI Generate for prompt-based image creation and image remixing, plus AI-assisted background removal, subject isolation, and clip masking. Corel also has a refreshed interface, improved stability, and app launch times around three times faster or more.

Why Does Purchasing Choice Matter to Small Businesses?

Software procurement affects both cash flow and access to future updates. CorelDRAW Graphics Suite is offered through a subscription, a one-time purchase for perpetual use, or a business license with maintenance.

Subscribers and maintenance customers receive product updates, CorelDRAW Web, added content, support for the latest operating systems and technologies, and a monthly AI credit allowance. Unlike a subscription, if business license customers choose to discontinue their maintenance, they get to keep the last version of the software that they received, forever. A one-time purchase permits perpetual use of the purchased version, though certain subscriber and maintenance features, apps, and workflows are not included.

CorelDRAW vs. Adobe Illustrator: How Do They Compare for Small Businesses?

Both CorelDRAW and Adobe Illustrator support professional vector artwork for logos, signage, apparel graphics, print, and digital media. Their product structures differ.

Illustrator is available as a subscription, either through a Creative Cloud membership or a single app plan. CorelDRAW Graphics Suite offers subscription and perpetual purchasing routes for a full suite of vector illustration, page layout, photo editing, and font management tools.

For businesses already using several Creative Cloud applications, Illustrator can fit within that existing software environment. Print shops comparing the two may prefer CorelDRAW for its streamlined workflow, production-specific tools, and flexible licensing options.

For small businesses looking for an alternative to Adobe Illustrator, particularly those weighing ongoing subscription costs, CorelDRAW's perpetual licensing option can be a deciding factor. Both CorelDRAW Graphics Suite and Adobe Creative Cloud include multiple applications for design and image editing, so the distinction is not simply the number of tools provided.

CorelDRAW instead offers graphic design and true multipage layout within the CorelDRAW application, integrated Pantone Color Libraries at no additional cost, and production tools developed for print and sign work. Together with subscription and one-time purchase options, these features give small businesses greater flexibility when choosing software for their workflows and budgets.

What Is the Practical Takeaway?

Consumer365's assessment places production readiness at the heart of the small-business software decision. CorelDRAW Graphics Suite 2026 covers design creation, image work, typography, proofing, separations, and final output while offering several ways to purchase and maintain the software.

The findings suggest that small print businesses should evaluate design software according to the full job cycle, including how files enter the shop, how color is checked, how large-format work is prepared, and how finished assets reach production.

Please visit the Consumer365 website for a more in-depth analysis.

About Corel

Corel is a global software company headquartered in Ottawa, Canada, with more than 100 million users in over 75 countries. Founded in 1985, Corel has built a strong reputation for innovation and usability in graphics, digital‑media, and productivity software. Its product portfolio includes vector illustration (CorelDRAW Graphics Suite), natural‑media painting (Corel Painter), photo editing (Corel PaintShop Pro), video production (Corel VideoStudio), and productivity tools (WordPerfect Office and WinZip). Corel's software is designed for both professionals and creative consumers and provides powerful features in an accessible, easy‑to-learn format. With a global footprint that includes major offices in the US, UK, Germany, China, Taiwan and Japan, Corel continues to expand its reach while maintaining a close connection with its user community.

About Consumer365.org: Consumer365 provides consumer news and industry insights. As an affiliate, Consumer365 may earn commissions from sales generated using links provided.

SOURCE Consumer365.org

21%

more press release views with 

Request a Demo